Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)

Long-term outcomes after radical prostatectomy are usually favourable. In those indicated for postoperative RT and considered suitable for no, short-term, or long-term ADT, there was no evidence of improvement with addition of ADT. Future research should focus on patients at a higher risk of metastases in whom improvements are required more urgently.

Authors

Institutions

Publication Details

Journal
European Urology
Published
2024-08-31
DOI
https://doi.org/10.1016/j.eururo.2024.07.026
Citations
27
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
11.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)

Charles Catton, Raj Persad, Mahesh Parmar, Adrian David Cook et al.
27 citations
European Urology
Prostate Cancer Treatment and Research
11.31
article

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)

Charles Catton, Raj Persad, Mahesh Parmar, Adrian David Cook, Heather Payne, William Cross, Claire Amos, René Horsleben Petersen, Fred Saad, Matthew R. Sydes, Wendy R. Parulekar, Noel W. Clarke, Jane Worlding, Rakesh Raman, Ian Sayers, Howard Kynaston, Chris Parker, John Logue, L. Bower
article en
27 citations

Abstract

Long-term outcomes after radical prostatectomy are usually favourable. In those indicated for postoperative RT and considered suitable for no, short-term, or long-term ADT, there was no evidence of improvement with addition of ADT. Future research should focus on patients at a higher risk of metastases in whom improvements are required more urgently.

European UrologyVol. 86(5)
University of Copenhagen (DK), Royal Marsden NHS Foundation Trust (GB), University Health Network (CA), Institute of Cancer Research (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Queen's University (CA), New Cross Hospital (GB), St James's University Hospital (GB), At Bristol (GB), Princess Margaret Cancer Centre (CA), University Hospitals Coventry and Warwickshire NHS Trust (GB), Rigshospitalet (DK), University of Manchester (GB), MRC Clinical Trials Unit at UCL (GB), Salford Royal Hospital (GB), Kent and Canterbury Hospital (GB), The Christie Hospital (GB), Centre Hospitalier de l’Université de Montréal (CA), The Prostate Centre (GB), University College London (GB), Cardiff University (GB)
Royal Marsden NHS Foundation Trust, UK Research and Innovation, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Cancer Research UK, National Institute for Health and Care Research, Canadian Cancer Society, University College London, Medical Research Council
Openalex Percentile: Top 1%
Prostate Cancer Treatment and Research
11.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.